References
- Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-naive patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147–56
- Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther 2010;12(1 Suppl):S79–S85
- Lee IT, Liu HC, Liau YJ, et al. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract 2009;15:699–703
- Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836–48
- Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948–62
- Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231–8
- Baser O, Bouchard J, Deluzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe. Adv Ther 2010;27:94–104
- Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712–25
- Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29(spec no):1294–305
- Lee LJ, Li Q, Reynolds MW, et al. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ 2011;14:75–86
- Niskanen L. A clinical and health economic review of a prefilled insulin pen. Curr Med Res Opin 2010;26:2431–9
- Molife C, Lee LJ, Shi L, et al. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther 2009;11:529–38
- Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin 2008;24:2413–22
- Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med 2008;120:172–9
- Wintergerst KA, Hinkle KM, Barnes CN, et al. The impact of health insurance coverage on pediatric diabetes management. Diabetes Res Clin Pract 2010;90:40–4
- Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430–2
- Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240–50
- Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144–51
- Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30
- Kuo Y-F, Raji MA, Markides KS, et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003;26:3054–60
- Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589–600
- Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Manag Care 2009;18:47–53
- Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74–109